Transition falls after missing AD endpoint
Transition Therapeutics Inc. (TSX:TTH; NASDAQ:TTHI) plunged C$7.99 (73%) to C$2.92 in Toronto and fell $6.74 (74%) to $2.35 on NASDAQ on Wednesday after scyllo-inositol ( ELND005) missed the primary endpoint in a Phase II/III trial to treat agitation and aggression in patients with Alzheimer's disease. Transition said it will consult an external advisory committee to determine future development plans for the small molecule that disaggregates beta amyloid fibrils. It did not respond to inquiries.
The primary endpoint of the 350-patient study was change in Neuropsychiatric Inventory-Clinician (NPI-C) scale of agitation and aggression. Transition said treatment and placebo groups showed a significant improvement from baseline, but the placebo group had a greater than expected reduction in agitation and aggression. ...